Processa Pharmaceuticals, Inc.
PCSAHealthcare|Biotechnology|US
$1.93
+0.09 (+4.89%)
DCF Value
$3.49
Cash / Share
$0.07
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02030067 Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | Solid Tumor, Metastatic Bladder Cancer | P1P2 | Completed | 127 | Open-label | RX-3117 |
| NCT03189914 RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | P1P2 | Completed | 46 | Open-label | RX-3117 |
| NCT04800562 A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica | Necrobiosis Lipoidica | P2 | Terminated | 4 | RCT, Double-blind | PCS499 |
| NCT01978366 Open Label Extension Study of HT-100 in Patients With DMD | Duchenne Muscular Dystrophy | P2 | Terminated | 17 | Open-label | HT-100 |
| NCT05270460 Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis | Gastroparesis | P2 | Completed | 25 | RCT, Double-blind | PCS12852, Placebo |
| NCT06568692 A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Breast Cancer, TNBC - Triple-Negative Breast Cancer | P2 | Terminated | 20 | RCT, Open-label | PCS6422 and capecitabine, Capecitabine |
| NCT01847573 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | P1P2 | Terminated | 17 | Open-label | HT-100 |
| NCT03698864 A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica | Necrobiosis Lipoidica | P2 | Completed | 12 | Open-label | PCS499 |
| NCT04861987 A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors | Advanced Cancer, Refractory Cancer | P1 | Completed | 23 | Open-label | PCS6422 and capecitabine |
| NCT03836222 Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects | Healthy | P1 | Completed | 18 | Open-label | PCS499, Trental |